Mumbai, India, and Naples, Florida, U.S., September 28, 2026
Lupin Limited has reached an important U.S. regulatory milestone after receiving tentative approval from the U.S. Food and Drug Administration (FDA) for its Apixaban Oral Suspension 1.25 mg/mL. The novel liquid formulation was submitted through the 505(b)(2) regulatory pathway and is designed to provide an alternative oral administration option for adults requiring anticoagulation therapy. The development is particularly relevant for patients who may experience difficulty swallowing conventional tablets. Apixaban is the active pharmaceutical ingredient in Eliquis®, and Lupin’s formulation represents an effort to expand available administration options for an established anticoagulant therapy.
Lupin Advances Novel Liquid Apixaban Formulation
The Apixaban Oral Suspension 1.25 mg/mL is being developed as a liquid formulation of apixaban, an oral anticoagulant used in the management of several thromboembolic conditions. By developing a suspension rather than a conventional tablet, Lupin is targeting an administration challenge faced by some adult patients who require anticoagulation but have difficulty swallowing solid oral dosage forms. The company says the formulation provides an alternative administration option while delivering the same active pharmaceutical ingredient used in Eliquis. The FDA’s tentative approval was obtained through the 505(b)(2) pathway, a regulatory route that can be used for certain drug applications where at least some of the information needed for approval comes from studies that were not conducted by or for the applicant. For Lupin, the regulatory milestone reflects its strategy of developing differentiated formulations alongside its broader portfolio of generics, complex generics and specialty medicines. The company maintains a substantial pharmaceutical manufacturing and research presence across global markets.
Potential Alternative for Patients With Swallowing Challenges
One of the key potential advantages of an oral suspension formulation is administration flexibility. Patients who have difficulty swallowing tablets can face challenges with conventional solid dosage forms, making alternative formulations an important area of pharmaceutical development. Lupin says its apixaban suspension is intended for adult patients requiring anticoagulation therapy, including those who may have difficulty swallowing tablets. Apixaban belongs to the class of direct oral anticoagulants (DOACs) and works by inhibiting Factor Xa, a protein involved in the blood-clotting process. The active ingredient is already established in clinical practice through Eliquis, while Lupin’s development focuses on providing the medicine in a different dosage form. The company’s announcement does not indicate that the tentative approval represents a new therapeutic indication for apixaban; rather, it concerns the development of a novel oral suspension formulation. For cGxP.wire readers, the story is notable because formulation innovation can address practical treatment challenges even when the underlying active pharmaceutical ingredient is already well established. Alternative dosage forms, particularly liquid formulations, can be relevant to patient administration, medication access and pharmaceutical product development.
Advertisement
U.S. Manufacturing Planned After Final Approval
Lupin stated that, upon final FDA approval, the Apixaban Oral Suspension will be manufactured at its facility in Somerset, New Jersey. The company plans to leverage its U.S.-based manufacturing capabilities to support product quality and supply reliability. The distinction between tentative and final approval remains important, as the announcement does not indicate that the product is yet commercially available in the United States. The development adds another product candidate to Lupin’s expanding U.S. portfolio, which spans complex formulations, specialty medicines, generics and biosimilars. The company has continued to pursue differentiated pharmaceutical products aimed at addressing specific patient and healthcare-system needs. The apixaban suspension program demonstrates this approach by focusing on dosage-form innovation around an established anticoagulant therapy.
With the FDA tentative approval now secured, the next regulatory milestone will be final approval, after which Lupin expects to manufacture the product in the United States. If finalized, the formulation could provide an additional administration option for adults requiring apixaban-based anticoagulation, particularly those for whom swallowing conventional tablets presents a challenge.
Source: Lupin press release
